3XV Stock Overview
A medical technology company, develops and markets machines and perfusion solutions for assessing usable organs and maintains in optimal condition pending transplantation in Sweden. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Xvivo Perfusion AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 29.28 |
| 52 Week High | SEK 46.80 |
| 52 Week Low | SEK 22.34 |
| Beta | 1.98 |
| 1 Month Change | 15.73% |
| 3 Month Change | -29.78% |
| 1 Year Change | -12.60% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -4.16% |
Recent News & Updates
Recent updates
Shareholder Returns
| 3XV | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 1.7% | 1.2% | 0.5% |
| 1Y | -12.6% | -9.0% | 14.4% |
Return vs Industry: 3XV underperformed the German Medical Equipment industry which returned -8.9% over the past year.
Return vs Market: 3XV underperformed the German Market which returned 14.6% over the past year.
Price Volatility
| 3XV volatility | |
|---|---|
| 3XV Average Weekly Movement | 10.2% |
| Medical Equipment Industry Average Movement | 6.4% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in DE Market | 12.8% |
| 10% least volatile stocks in DE Market | 3.1% |
Stable Share Price: 3XV's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 3XV's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 193 | Christoffer Rosenblad | www.xvivogroup.com |
Xvivo Perfusion AB (publ), a medical technology company, develops and markets machines and perfusion solutions for assessing usable organs and maintains in optimal condition pending transplantation in Sweden. It operates through Thoracic; Abdominal; Services; and other segments. The company offers Kidney Assist Transport, a portable device that allows hypothermic pulsatile perfusion of donor kidneys with oxygenated solution for up to 24 hours; Liver Assist that provides clinicians a choice of perfusion protocols whether hypothermic, normothermic, sub-normothermic, or a combination; XVIVO System (XPS), a comprehensive ex vivo lung perfusion (EVLP) platform that offers an overview of the entire process; and STEEN Solution, a buffered extracellular solution intended for the assessment of isolated lungs after removal from the donor in preparation for eventual transplantation into a recipient.
Xvivo Perfusion AB (publ) Fundamentals Summary
| 3XV fundamental statistics | |
|---|---|
| Market cap | €926.23m |
| Earnings (TTM) | €12.55m |
| Revenue (TTM) | €78.32m |
73.8x
P/E Ratio11.8x
P/S RatioIs 3XV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 3XV income statement (TTM) | |
|---|---|
| Revenue | SEK 854.98m |
| Cost of Revenue | SEK 213.30m |
| Gross Profit | SEK 641.68m |
| Other Expenses | SEK 504.69m |
| Earnings | SEK 137.00m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
Jul 11, 2025
| Earnings per share (EPS) | 4.35 |
| Gross Margin | 75.05% |
| Net Profit Margin | 16.02% |
| Debt/Equity Ratio | 0% |
How did 3XV perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/19 13:40 |
| End of Day Share Price | 2025/05/16 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Xvivo Perfusion AB (publ) is covered by 11 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Dylan van Haaften | Bryan Garnier & Co |
| Maria Vara Fernández | Bryan Garnier & Co |
| Kristofer Liljeberg-Svensson | Carnegie Investment Bank AB |